Union Budget 2026–27 Focuses on Pharma Industry and Patient Welfare
The Union Budget 2026–27 presented today by the Hon’ble Union Finance Minister includes several far-sighted and progressive announcements with a strong focus on the pharmaceutical industry, research, innovation, and patient welfare. The budget is expected to strengthen India’s position as a global pharmaceutical hub while ensuring the availability of affordable, safe, and quality medicines for the common patient.
AIOCD Expresses Gratitude to the Government
Expressing gratitude to the Government, J. S. Shinde, President, and Rajiv Singhal, General Secretary, of the All India Organization of Chemists and Druggists (AIOCD) stated that the proposal to grant complete exemption from Basic Customs Duty (BCD) on 36 life-saving medicines used for cancer and other serious diseases is a highly sensitive and humane decision. This move will significantly reduce treatment costs and make critical therapies more affordable for patients.
In addition, the inclusion of 37 new medicines and 13 new programmes under patient assistance initiatives clearly reflects the Government’s commitment to keeping patient welfare at the highest priority.
Boost to Ayurveda and Bio-Pharma Manufacturing
The Budget has provided strong impetus to Ayurveda and bio-pharma manufacturing through the announcement of three dedicated Ayurvedic AIIMS and the establishment of national-level testing laboratories for Ayurvedic medicines.
Along with the launch of the five-year Biopharma SHAKTI programme and a proposed investment of ₹10,000 crore, the Government aims to develop a robust ecosystem for biologics and biosimilar manufacturing. The initiative also targets the training of one lakh specialized healthcare professionals over the next five years, strengthening the Aatmanirbhar Bharat initiative and positioning India as a global hub for bio-pharma and traditional medicine production.
Strengthening Education, Research and Innovation
The proposal to establish three new National Institutes of Pharmaceutical Education and Research (NIPERs) and to upgrade seven existing institutions will provide fresh momentum to pharmaceutical education, quality research, innovation, and skilled human resource development. Over time, this will act as a strong bridge between industry and academia.
The announcement of a nationwide network of more than 1,000 accredited clinical trial sites will further promote innovation-driven research and strengthen India’s presence on the global clinical research map.
Furthermore, the special emphasis on drug discovery and Research & Development (R&D) incentives marks a decisive step towards transforming India into an innovation-driven pharmaceutical economy.
A Visionary and People-Centric Budget
On behalf of AIOCD, sincere appreciation and gratitude are extended to the Hon’ble Finance Minister and the Government of India for presenting a balanced, visionary, and people-centric budget. This budget is expected to usher in a new era of hope and confidence for the pharmaceutical industry, the healthcare ecosystem, and millions of patients across the country.